Solubility Enhancement and Formulation Development of Paliperidone

Abstract

The clinical efficacy of PLDN was limited by its poor solubility. The marketed preparations focused on extended the release of drug dosage forms with an objective to develop once a day dosing formulation. However, the poor bioavailability (28%) of the commercial dosage form (ER tablets) due to poor solubility and less intestinal absorption remains unaddressed. Therefore, the aim of this research work was to provide a suitable solubility enhancement technique(s) to resolve poor solubility problem associated with PLDN. Another objective of the current research work was to develop a novel, patient compliant and efficacious nasal drug delivery system with an intention to provide rapid onset of action and improved bioavailability newline